Discover the Latest Treatments in Managing Non-Small Cell Lung Cancer
Friday, June 20, 2014
"The value of the educational program comes directly from the expertise of the presenters and the insights they provide." — Andrew Churg, MS, FASCP
Non-small cell lung cancer (NSCLC) has become a major platform for studying molecular targeted agents to personalize therapy for patients. Healthcare professionals involved in the care of patients in the community setting are constantly challenged to stay current with recent advances in the management of NSCLC. Clinical integration is critical to improving the efficiency and effectiveness of care.
ASCP will present a cased-based and informative session, “A Multidisciplinary Approach for the Management of Advanced Non-small Cell Lung Cancer: Diagnosis, Personalized Assessment, and Treatment with Targeted and Immunotherapeutic Agents,” on Wednesday, July 23 from 5 to 7 p.m. at the Holiday Inn Mart Plaza, Chicago.
This multi-specialty session, offered in conjunction with Pathology Updates, July 21–25, is FREE and open to all pathologists, oncologists, and their colleagues. One need not register for Pathology Updates to attend the special session on NSCLC.
This program, funded by independent education grant from Genentech and Boehringer Ingelheim, will model best practices in communication between pathologists and oncologists—key members of the multidisciplinary cancer care team—to ensure accurate diagnosis and management of NSCLC.
“The value of the educational program comes directly from the expertise of the presenters and the insights they provide,” says Andrew Churg, MS, FASCP, Chair of the ASCP Educational Courses Committee.
To register for this session, click here.